← Leaderboards
Meenakshi Swaminathan Madhur
Emory University
$6,330,839
Attributed
$6,854,879
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2008–25$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,854,879 · 5
By mechanism
R01$3,199,341 · 2
DP2$2,828,332 · 1
K08$722,574 · 1
F32$104,632 · 1
Top collaborators
- Jonathan David Brown1 shared
- Amanda C Doran1 shared
Most similar at Emory University
Same institution · by research overlap
- Kathy K Griendling$20,428,027
- Sampath Parthasarathy$11,379,014
- William Lewis$16,644,836
- Stefan G Sarafianos$26,943,765
- Caleb Benjamin Kallen$1,630,427
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsResponseBlood PressureT-LymphocyteHypertensionMediatingProductionMorbidity - Disease RateFunctional DisorderOrganStrokeCytokineNormotensiveImmuneInflammatoryNew Therapeutic TargetInflammationImmune SystemAdultAngiotensin IiRisk FactorsPathway InteractionsLeadKidney
Grant awards (16)
Hypertension-associated Trained Immunity in Myeloid Cells is a Determinant of Atherosclerosis$786,060
R01 · FY2025 · HL
Immune Modulation in Hypertension$566,364
R01 · FY2025 · HL · contact PI
Immune Modulation in Hypertension$578,011
R01 · FY2024 · HL · contact PI
Immune Modulation in Hypertension$634,453
R01 · FY2023 · HL · contact PI
Immune Modulation in Hypertension$634,453
R01 · FY2022 · HL · contact PI
Immunophenotyping of Human Hypertension Using Single Cell Multiplex Mass Cytometry to Identify Novel Therapeutic Targets$471,000
DP2 · FY2021 · HL · contact PI
Immunophenotyping of Human Hypertension Using Single Cell Multiplex Mass Cytometry to Identify Novel Therapeutic Targets$2,332
DP2 · FY2019 · HL · contact PI
Diverse Roles of Interleukin 17 Isoforms in the Pathogenesis of Hypertension$157,248
K08 · FY2018 · HL · contact PI
Diverse Roles of Interleukin 17 Isoforms in the Pathogenesis of Hypertension$157,248
K08 · FY2017 · HL · contact PI
Immunophenotyping of Human Hypertension Using Single Cell Multiplex Mass Cytometry to Identify Novel Therapeutic Targets$2,355,000
DP2 · FY2016 · HL · contact PI
Diverse Roles of Interleukin 17 Isoforms in the Pathogenesis of Hypertension$96,946
K08 · FY2016 · HL · contact PI
Diverse Roles of Interleukin 17 Isoforms in the Pathogenesis of Hypertension$60,302
K08 · FY2016 · HL · contact PI
Diverse Roles of Interleukin 17 Isoforms in the Pathogenesis of Hypertension$125,415
K08 · FY2015 · HL · contact PI
Diverse Roles of Interleukin 17 Isoforms in the Pathogenesis of Hypertension$125,415
K08 · FY2014 · HL · contact PI
Role of T Cell and Vascular NADPH Oxidases in Angiotensin II Induced Hypertension$53,354
F32 · FY2009 · HL · contact PI
Role of T Cell and Vascular NADPH Oxidases in Angiotensin II Induced Hypertension$51,278
F32 · FY2008 · HL · contact PI